vs

Side-by-side financial comparison of Catalyst Bancorp, Inc. (CLST) and Opus Genetics, Inc. (IRD). Click either name above to swap in a different company.

Opus Genetics, Inc. is the larger business by last-quarter revenue ($3.9M vs $2.7M, roughly 1.5× Catalyst Bancorp, Inc.). On growth, Catalyst Bancorp, Inc. posted the faster year-over-year revenue change (1.4% vs -10.2%). Over the past eight quarters, Opus Genetics, Inc.'s revenue compounded faster (50.3% CAGR vs 12.6%).

Catalyst Bancorp, Inc. is a U.S.-based financial holding company that operates community banking subsidiaries. It provides a full range of retail and commercial banking products including checking and savings accounts, small business loans, residential mortgages, personal lending, and wealth management services, primarily serving local regional markets across the U.S. with a focus on individual consumers and small business clients.

Opus Genetics, Inc. is a clinical-stage biotechnology company specializing in the development of targeted gene therapies for inherited retinal diseases. It focuses on addressing unmet medical needs for patients living with rare, vision-threatening ocular conditions, with operations centered on advancing accessible therapeutic candidates for global rare disease patient populations.

CLST vs IRD — Head-to-Head

Bigger by revenue
IRD
IRD
1.5× larger
IRD
$3.9M
$2.7M
CLST
Growing faster (revenue YoY)
CLST
CLST
+11.6% gap
CLST
1.4%
-10.2%
IRD
Faster 2-yr revenue CAGR
IRD
IRD
Annualised
IRD
50.3%
12.6%
CLST

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CLST
CLST
IRD
IRD
Revenue
$2.7M
$3.9M
Net Profit
$456.0K
Gross Margin
Operating Margin
20.8%
Net Margin
17.2%
Revenue YoY
1.4%
-10.2%
Net Profit YoY
-27.2%
53.0%
EPS (diluted)
$0.13

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CLST
CLST
IRD
IRD
Q4 25
$2.7M
$3.9M
Q3 25
$2.8M
$3.1M
Q2 25
$2.8M
$2.9M
Q1 25
$2.9M
$4.4M
Q4 24
$2.5M
$4.3M
Q3 24
$3.2M
$3.9M
Q2 24
$2.8M
$1.1M
Q1 24
$2.1M
$1.7M
Net Profit
CLST
CLST
IRD
IRD
Q4 25
$456.0K
Q3 25
$489.0K
$-17.5M
Q2 25
$521.0K
$-7.4M
Q1 25
$586.0K
$-8.2M
Q4 24
$626.0K
Q3 24
$447.0K
$-7.5M
Q2 24
$527.0K
$-7.8M
Q1 24
$-4.7M
$-7.1M
Operating Margin
CLST
CLST
IRD
IRD
Q4 25
20.8%
Q3 25
21.7%
-269.9%
Q2 25
22.5%
-309.0%
Q1 25
24.7%
-227.2%
Q4 24
31.2%
Q3 24
17.6%
-207.1%
Q2 24
23.0%
-748.9%
Q1 24
-284.6%
-450.5%
Net Margin
CLST
CLST
IRD
IRD
Q4 25
17.2%
Q3 25
17.7%
-566.9%
Q2 25
18.5%
-257.5%
Q1 25
20.1%
-187.5%
Q4 24
25.3%
Q3 24
14.2%
-194.6%
Q2 24
18.7%
-698.3%
Q1 24
-224.0%
-415.3%
EPS (diluted)
CLST
CLST
IRD
IRD
Q4 25
$0.13
Q3 25
$0.13
$-0.25
Q2 25
$0.14
$-0.12
Q1 25
$0.16
$-0.24
Q4 24
$0.13
Q3 24
$0.11
$-0.29
Q2 24
$0.13
$-0.30
Q1 24
$-1.15
$-0.29

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CLST
CLST
IRD
IRD
Cash + ST InvestmentsLiquidity on hand
$25.2M
$45.1M
Total DebtLower is stronger
$14.7M
Stockholders' EquityBook value
$81.7M
$15.3M
Total Assets
$282.9M
$50.2M
Debt / EquityLower = less leverage
0.18×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CLST
CLST
IRD
IRD
Q4 25
$25.2M
$45.1M
Q3 25
$37.3M
$30.8M
Q2 25
$40.1M
$32.4M
Q1 25
$40.3M
$41.8M
Q4 24
$44.3M
$30.3M
Q3 24
$45.8M
$36.6M
Q2 24
$75.5M
$41.4M
Q1 24
$76.0M
$47.2M
Total Debt
CLST
CLST
IRD
IRD
Q4 25
$14.7M
Q3 25
$14.7M
Q2 25
Q1 25
Q4 24
$9.6M
Q3 24
$29.5M
Q2 24
$30.3M
Q1 24
$29.4M
Stockholders' Equity
CLST
CLST
IRD
IRD
Q4 25
$81.7M
$15.3M
Q3 25
$81.6M
$6.0M
Q2 25
$80.8M
$17.5M
Q1 25
$80.6M
$5.1M
Q4 24
$80.2M
$6.7M
Q3 24
$81.7M
$34.3M
Q2 24
$81.0M
$40.6M
Q1 24
$81.3M
$46.1M
Total Assets
CLST
CLST
IRD
IRD
Q4 25
$282.9M
$50.2M
Q3 25
$283.8M
$36.1M
Q2 25
$273.8M
$38.7M
Q1 25
$271.6M
$48.2M
Q4 24
$276.7M
$36.9M
Q3 24
$280.6M
$40.4M
Q2 24
$295.3M
$44.8M
Q1 24
$282.0M
$51.8M
Debt / Equity
CLST
CLST
IRD
IRD
Q4 25
0.18×
Q3 25
0.18×
Q2 25
Q1 25
Q4 24
0.12×
Q3 24
0.36×
Q2 24
0.37×
Q1 24
0.36×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CLST
CLST
IRD
IRD
Operating Cash FlowLast quarter
$3.3M
$-35.3M
Free Cash FlowOCF − Capex
$3.1M
FCF MarginFCF / Revenue
116.8%
Capex IntensityCapex / Revenue
7.1%
Cash ConversionOCF / Net Profit
7.21×
TTM Free Cash FlowTrailing 4 quarters
$5.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CLST
CLST
IRD
IRD
Q4 25
$3.3M
$-35.3M
Q3 25
$912.0K
$-6.2M
Q2 25
$1.2M
$-10.3M
Q1 25
$427.0K
$-9.0M
Q4 24
$3.2M
$-25.6M
Q3 24
$896.0K
$-5.1M
Q2 24
$1.4M
$-7.3M
Q1 24
$247.0K
$-5.7M
Free Cash Flow
CLST
CLST
IRD
IRD
Q4 25
$3.1M
Q3 25
$827.0K
Q2 25
$1.1M
Q1 25
$361.0K
Q4 24
$2.7M
Q3 24
$771.0K
Q2 24
$1.2M
Q1 24
$223.0K
FCF Margin
CLST
CLST
IRD
IRD
Q4 25
116.8%
Q3 25
29.9%
Q2 25
39.7%
Q1 25
12.4%
Q4 24
110.9%
Q3 24
24.5%
Q2 24
41.5%
Q1 24
10.7%
Capex Intensity
CLST
CLST
IRD
IRD
Q4 25
7.1%
Q3 25
3.1%
Q2 25
1.2%
Q1 25
2.3%
Q4 24
17.4%
Q3 24
4.0%
Q2 24
8.0%
Q1 24
1.1%
Cash Conversion
CLST
CLST
IRD
IRD
Q4 25
7.21×
Q3 25
1.87×
Q2 25
2.21×
Q1 25
0.73×
Q4 24
5.07×
Q3 24
2.00×
Q2 24
2.64×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons